Tables

TABLE 1 CLINICAL TRIALS OF NEUROINTERVENTIONAL DEVICES 23
TABLE 2 PARKINSON DISEASES DRUGS: PIPELINE PRODUCTS 25
TABLE 3 PATENT EXPIRATION OF PARKINSON DISEASE DRUGS 37
TABLE 4 PARKINSON DISEASES MARKET REVENUE BY DRUG TYPE' 2017-2024 ($MILLION) 40
TABLE 5 PARKINSON DISEASES MARKET REVENUE BY REGIONS' 2017-2024 ($MILLION) 49
TABLE 6 NOVARTIS AG: OFFERINGS 58
TABLE 7 NOVARTIS AG: RECENT DEVELOPMENTS 59
TABLE 8 GLAXOSMITHKLINE PLC: OFFERINGS 66
TABLE 9 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS 67
TABLE 10 F. HOFFMANN-LA ROCHE LTD.: OFFERINGS 72
TABLE 11 F. HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS 73
TABLE 12 ABBVIE INC.: OFFERINGS 78
TABLE 13 ABBVIE INC: RECENT DEVELOPMENTS 78
TABLE 1 MERCK & CO: PRODUCT OFFERINGS 83
TABLE 2 MERCK & CO: RECENT DEVELOPMENTS 83
TABLE 3 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT OFFERINGS 88
TABLE 4 TEVA PHARMACEUTICAL INDUSTRIES LTD: RECENT DEVELOPMENTS 88
TABLE 5 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: OFFERINGS 93
TABLE 6 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: RECENT DEVELOPMENTS 94
TABLE 7 BOEHRINGER INGELHEIM GMBH: OVERVIEW 99
TABLE 8 BOEHRINGER INGELHEIM: RECENT DEVELOPMENTS 100
TABLE 9 AMNEAL PHARMACEUTICAL INDUSTRIES LTD.: OVERVIEW 101
TABLE 10 AMNEAL PHARMACEUTICAL: RECENT DEVELOPMENTS 101
TABLE 11 WOCKHARDT.: OVERVIEW 102
TABLE 12 STADA ARZNEIMITTEL AG: OVERVIEW 102
TABLE 13 STADA ARZNEIMITTEL AG: RECENT DEVELOPMENTS 103
TABLE 14 PFIZER INC. OVERVIEW 104
TABLE 15 PFIZER INC.: RECENT DEVELOPMENTS 104
TABLE 16 SUN PHARMACEUTICALS: OVERVIEW 106
TABLE 17 SUN PHARMACEUTICALS: RECENT DEVELOPMENTS 106

?

LIST OF FIGURE

Charts

CHART 1 GLOBAL PHARMACEUTICAL R&D SPENDING (2010-2016) 10
CHART 2 R&D INVESTMENT BY TOP 10 COMPANIES ($BN) 11
CHART 3 RESEARCH METHODOLOGY OF GLOBAL PARKINSONS DISEASES MARKET 16
CHART 4 GLOBAL PARKINSON DISEASE MARKET REVENUE' 2017-2024 ($MILLION) 19
CHART 5 SEGMENTATION OF GLOBAL PARKINSON DISEASES DRUGS MARKET 30
CHART 6 PORTER 5 FORCES OF PARKINSON DISEASES MARKET 31
CHART 7 PEST ANALYSIS OF PARKINSON DISEASES MARKET 32
CHART 8 MARKET DYNAMICS - DRO ANALYSIS 33
CHART 9 DRO - IMPACT ANALYSIS OF GLOBAL PARKINSON DISEASES MARKET 38
CHART 10 KEY STAKEHOLDERS 39
CHART 11 PARKINSON DISEASE MARKET BY DRUG TYPE' 2017 VS 2024 (%) 40
CHART 12 LEVADOPA DRUGS MARKET REVENUE' 2017-2024 ($MILLION) 41
CHART 13 DOPAMINE AGONIST MARKET REVENUE' 2017-2024 ($MILLION) 42
CHART 14 MAO-B MARKET REVENUE' 2017-2024 ($MILLION) 43
CHART 15 COMT INHIBITORS MARKET REVENUE' 2017-2024 ($MILLION) 44
CHART 16 ANTICHOLINERGICS MARKET REVENUE' 2017-2024 ($MILLION) 45
CHART 17 OTHER DRUGS MARKET REVENUE' 2017-2024 ($MILLION) 46
CHART 18 PARKINSON DISEASES MARKET BY REGIONAL SEGMENTATION' 2017 VS 2024 (%) 49
CHART 19 PARKINSON DISEASES MARKET REVENUE IN THE NORTH AMERICA REGION' 2017-2023 ($MILLION) 50
CHART 20 THE PREVALENCE RATE OF PD IN EUROPE 51
CHART 21 PARKINSON DISEASES MARKET REVENUE IN THE EUROPEAN REGION' 2017-2023 ($MILLION) 52
CHART 22 PARKINSON DISEASES MARKET REVENUE IN THE APAC REGION' 2017-2024 ($MILLION) 53
CHART 23 PARKINSON DISEASES MARKET REVENUE IN REST OF THE WORLD' 2017-2024 ($MILLION) 54
CHART 24 NOVARTIS AG: OVERVIEW SNAPSHOT 58
CHART 25 NOVARTIS AG: BUSINESS UNITS 62
CHART 26 NOVARTIS AG: GEOGRAPHICAL PRESENCE 63
CHART 27 NOVARTIS AG: SWOT ANALYSIS 64
CHART 28 GLAXOSMITHKLINE PLC: OVERVIEW SNAPSHOT 66
CHART 29 GLAXOSMITHKLINE PLC: BUSINESS UNITS 69
CHART 30 GLAXOSMITHKLINE PLC: GEOGRAPHIC PRESENCE 70
CHART 31 GLAXOSMITHKLINE PLC: SWOT ANALYSIS 71
CHART 32 F. HOFFMANN-LA ROCHE LTD.: OVERVIEW SNAPSHOT 72
CHART 33 F. HOFFMANN.LA ROCHE LTD.: BUSINESS UNITS 75
CHART 34 F. HOFFMANN-LA ROCHE: GEOGRAPHICAL PRESENCE 76
CHART 35 F. HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS 77
CHART 36 ABBVIEE INC: OVERVIEW SNAPSHOT 80
CHART 37 ABBVIEE INC.: GEOGRAPHIC PRESENCE 81
CHART 38 ABBVIE INC.: SWOT ANALYSIS 82
CHART 39 MERCK & CO: OVERVIEW SNAPSHOT 84
CHART 40 MERCK & CO: BUSINESS UNITS 84
CHART 41 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE 85
CHART 42 MERCK & CO: SWOT ANALYSIS 86
CHART 43 TEVA PHARMACEUTICAL INDUSTRIES LTD: OVERVIEW SNAPSHOT 89
CHART 44 TEVA PHARMACEUTICAL INDUSTRIES LTD: BUSINESS UNITS 90
CHART 45 TEVA PHARMACEUTICAL INDUSTRIES LTD: GEOGRAPHICAL PRESENCE 91
CHART 46 TEVA PHARMACEUTICAL INDUSTRIES LTD: SWOT ANALYSIS 92
CHART 47 VALEANT PHARMACEUTICALS INTERNATIONAL INC: OVERVIEW SNAPSHOT 94
CHART 48 VALEANT PHARMACEUTICALS INTERNATIONAL INC: BUSINESS UNITS 96
CHART 49 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: GEOGRAPHICAL PRESENCE 97
CHART 50 VALEANT PHARMACEUTICALS INTERNATIONAL INC: SWOT ANALYSIS 97